Minimizing Bioavailability Variations with Oral Controlled Release Formulations

Kaushal, Aditya Mohan; Garg, Sanjay

doi:10.2165/00137696-200301020-00002

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To conquer this drug, it should be developed in a suitable dosage form that helps to prolong gastro-retention time and enhance the absorption of the drug. [1][2][3] The gastric residence time (GRT) of pharmaceutical dosage form is extended using gastroretentive dosage forms (GRDFs). The gastroretentive dosage forms can hold the drug inside the stomach.…”

Section: Introductionmentioning

confidence: 99%

Formulation and Evaluation of Bioadhesive Pulsatile Drug Delivery System of an Antihypertensive Drug

Janugade,

Singla

2024

IJPQA

View full text Add to dashboard Cite

The current research aimed to prepare and estimate bioadhesive pulsatile drug delivery system (BPDDS) of an antihypertensive drug, losartan potassium, containing the formulation of a fast-dissolving core tablet and a combination of core tablet to polymer coating to formulate (BPDDS) tablet through a direct compression procedure. The coating was completed by utilizing polymers ethyl cellulose and carbopol 934. Pre-compression and post-compression parameters, drug release, lag time and mucoadhesive examination was entirely assessed for the formulations. Altogether, estimation tests were found to be inside parameters. The expected lag time for hypertension is 8 hours; hence this lag time was achieved by using a bioadhesive pulsatile system. The optimized formulation showed 8 hours lag time with appropriate mucoadhesion for an equivalent period. Therefore, the BPDDS was greatest preventative substitute for drug which are the highest absorption in the stomach and for drugs which used to treat diseases with a circadian rhythm.

show abstract

Section: Introductionmentioning

confidence: 99%

Formulation and Evaluation of Bioadhesive Pulsatile Drug Delivery System of an Antihypertensive Drug

Janugade,

Singla

2024

IJPQA

View full text Add to dashboard Cite

show abstract

“…Others are reported to improve targeting for a specific site to reduce unwanted side effects. Still, a number of them mimic the circadian rhythm of particular diseases in order to optimize a drug's therapeutic power, potentially differentiating a brand and giving it a competitive edge over less effective drug (Kaushal and Garg, 2003).…”

Section: Introductionmentioning

confidence: 99%

Preclinical 28 days sub-chronic toxicity study of novel formulation of metoprolol tartrate on albino rats using statistical tool

Siddique¹,

Das²,

Abdul³

et al. 2018

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

The experimental study mainly focused on evaluation of sub-chronic oral toxicity of sustained formulation of metoprolol succinate. After the formulation development of multiparticulate sustained release capsules, there was an urgent need to analyze their in vivo bioavailability in healthy normal human volunteers. Prior to use in human population, a subchronic oral toxicity study was performed on Swiss Albino rats, of the final formulated product to assess the possible therapeutic outcome and related toxicity. The final objective of the study is to find out the pharmacological interaction between the drugs and the excipients that may lead to toxicity to human volunteers. The sustained release formulation of Metoprolol tartrateat was administered in different dose according to the 28 days of study dosing schedule in 48 albino Wistar rats of either sex (24 males and 24 females); periodical safety and efficacy observation were done followed by blood chemistry, hematology and histopathological examination at the end of the study. All the animals were found alive after the study period. No behavioral abnormalities were found in the study animals. Statistical analysis of the results including various parameters like body weight, blood chemistry, hematology and histopathological evaluation did not produce any major differences between control and treated groups. The reformulated sustained release hydroxy propyl methyl cellulose based granules of metoprolol tartrate did not cause any subchronic toxicity to the study animals under experimental conditions.

show abstract

Minimizing Bioavailability Variations with Oral Controlled Release Formulations

Cited by 2 publications

References 29 publications

Formulation and Evaluation of Bioadhesive Pulsatile Drug Delivery System of an Antihypertensive Drug

Formulation and Evaluation of Bioadhesive Pulsatile Drug Delivery System of an Antihypertensive Drug

Preclinical 28 days sub-chronic toxicity study of novel formulation of metoprolol tartrate on albino rats using statistical tool

Contact Info

Product

Resources

About